

Human milk oligosaccharides inhibit growth of group B *Streptococcus*

Received for publication, April 6, 2017. Published, Papers in Press, April 17, 2017. DOI 10.1074/jbc.M117.789974

Ann E. Lin[‡], Chloe A. Autran^{§¶}, Alexandra Szyszka^{§¶}, Tamara Escajadillo[‡], Mia Huang[¶], Kamil Godula[¶], Anthony R. Prudden^{**}, Geert-Jan Boons^{**}, Amanda L. Lewis^{††}, Kelly S. Doran^{‡§§}, Victor Nizet^{‡¶¶¶}, and Lars Bode^{§¶¶¶¶*1}

From the Divisions of [‡]Host-Microbe Systems and Therapeutics, [§]Neonatology, and [¶]Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, ^{¶¶}Department of Chemistry and Biochemistry, ^{¶¶¶}Skaggs School of Pharmacy and Pharmaceutical Sciences, and ^{**}Larsson-Rosenquist Foundation Mother-Milk-Infant Center of Research Excellence, University of California, San Diego, La Jolla, California 92093, ^{¶¶¶}Rady Children's Hospital, San Diego, California 92123, the ^{**}Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, the ^{††}Department of Molecular Microbiology and Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, and the ^{§§}Department of Biology and Center for Microbial Sciences, San Diego State University, San Diego, California 92182

Edited by Gerald W. Hart

Streptococcus agalactiae (group B *Streptococcus*, GBS) is a leading cause of invasive bacterial infections in newborns, typically acquired vertically during childbirth secondary to maternal vaginal colonization. Human milk oligosaccharides (HMOs) have important nutritional and biological activities that guide the development of the immune system of the infant and shape the composition of normal gut microbiota. In this manner, HMOs help protect against pathogen colonization and reduce the risk of infection. In the course of our studies of HMO-microbial interactions, we unexpectedly uncovered a novel HMO property to directly inhibit the growth of GBS independent of host immunity. By separating different HMO fractions through multidimensional chromatography, we found the bacteriostatic activity to be confined to specific non-sialylated HMOs and synergistic with a number of conventional antibiotic agents. Phenotypic screening of a GBS transposon insertion library identified a mutation within a GBS-specific gene encoding a putative glycosyltransferase that confers resistance to HMOs, suggesting that HMOs may function as an alternative substrate to modify a GBS component in a manner that impairs growth kinetics. Our study uncovers a unique antibacterial role for HMOs against a leading neonatal pathogen and expands the potential therapeutic utility of these versatile molecules.

Group B *Streptococcus* (GBS)² are Gram-positive bacteria that colonize the vaginal epithelium in 15–30% of healthy

women. GBS transmission to the newborn is associated with risk of pneumonia, septicemia, and meningitis (1–3). In the United States and other developed countries, implementation of universal antenatal GBS culture screening and administration of intrapartum antibiotic prophylaxis has reduced GBS incidence in the first few days of life; however, it has not had a similar impact on late-onset infections, which now represent approximately one-third of total cases (4). Up to half of all infants with late-onset GBS also develop meningitis, which carries a high incidence (>40%) of neurocognitive sequelae among survivors (5). In a recent meta-analysis, the overall incidence of GBS infection in infants >3 months of age in the Americas and Europe is ~0.53–0.67 cases/1000 births, with an overall case fatality rate of 7–10% (6). The emergence of antibiotic-resistant GBS strains has become an increasing concern (1, 7, 8).

Human milk oligosaccharides (HMOs) are a group of complex carbohydrates that are highly abundant in human milk (10–15 g/liter) but not in infant formula (reviewed in Ref. 9). HMOs are comprised of five monosaccharides: D-glucose (Glc), D-galactose (Gal), GlcNAc, L-fucose, and sialic acid (*N*-acetylneuraminic acid). The Gal-Glc disaccharide (lactose) backbone can be further elongated by up to 15 Gal-GlcNAc repeats and can be sialylated or fucosylated. Over 150 structurally distinct HMOs have been identified, comprised of neutral (non-sialylated) and acidic (sialylated) forms, and the amount and composition are highly variable between women (reviewed in Ref. 10).

HMOs are not digested by the infant and reach the colon intact, where they serve as metabolic substrates for specific, potentially beneficial bacteria and help shape the infant microbiome. HMOs also act as soluble receptor decoys to prevent attachment of microbial pathogens to the host (11–14). HMOs are partially absorbed and reach the systemic circulation of the

This work was supported by NHLBI, National Institutes of Health Programs of Excellence in Glycosciences Grant HL107150 (to V. N.), NIDDK, National Institutes of Health Grant P50DK064540 (PI: Hultgren) (to A. L. L.), and a PROMO fellowship from the German Academic Exchange Service (to A. S.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This article contains supplemental Figs. S1–S3.

¹ To whom correspondence should be addressed. Tel.: 858-246-1874; E-mail: lbode@ucsd.edu.

² The abbreviations used are: GBS, group B *Streptococcus*; HMO, human milk oligosaccharide; Glc, D-glucose; Gal, D-galactose; UPEC, uropathogenic *Escherichia coli*; pHMO, pooled human milk oligosaccharide; GOS, galactooligosaccharide(s); aHMO, acidic human milk oligosaccharide; nHMO, neu-

tral human milk oligosaccharide; LNT, lacto-*N*-tetraose; LNnT, lacto-*N*-neotetraose; LNnH, lacto-*N*-neohexaose; LNnFP, lacto-*N*-neofucopentaose I; LNDFHII, lacto-*N*-difucohexaose II; LnNO, lacto-*N*-neooctaose; LNnDFH, lacto-*N*-neodifucohexaose; LNnFPV, lacto-*N*-neofucopentaose; LNnFPV, lacto-*N*-fucopentaose V; THB, Todd-Hewitt broth; SF-RPMI 1640, serum-free RPMI 1640; ANOVA, analysis of variance.

Human milk oligosaccharides inhibit GBS growth




Figure 1. Human milk oligosaccharides inhibit GBS growth. A, bacteria were cultured for 4 h in SF-RPMI in the absence (solid lines) or presence (dashed lines) of pHMO in a 37 °C, 5% CO₂ incubator. Pa, *P. aeruginosa*; MRSA, methicillin-resistant *S. aureus*; GAS, group A *Streptococcus*. B, GBS serotype III strain COH1 was incubated with 1–10 mg/ml of pHMO in SF-RPMI. C, growth of three GBS strains of differing serotypes in the presence of pHMOs at the indicated concentrations. Relative growth represents cfu at the indicated point with respect to initial cfu inoculum × 100%. Solid line, no pHMOs; dotted line, with pHMOs; error bars, S.E. (n = 3). *, p < 0.05, one-way ANOVA, Tukey's multiple comparison's test.

infant (15, 16) and appear intact in the urine of breast-fed infants (17, 18), with the potential to exert effects in organs other than the gut and including the urinary tract. Most intriguingly, HMOs also appear in the urine of pregnant women as early as the end of the first trimester (19), suggesting that HMOs might already affect pregnant women and the growing fetus long before birth.

In a previous study, we demonstrated that HMOs regulate the host innate immune response in bladder epithelial cells to prevent invasion and cytotoxicity caused by uropathogenic *Escherichia coli* (UPEC) without any direct interference with bacterial growth (20). To delineate whether HMOs generate similar effects with other neonatal pathogens, we examined the effect of HMOs on GBS, which is commonly found in the urogenital tract of pregnant women. Unexpectedly, we found that HMOs directly inhibit the growth of GBS, a property not shared with UPEC, *Pseudomonas aeruginosa*, or *Staphylococcus aureus*. Further investigation revealed a unique aspect of HMOs that causes a significant GBS growth defect.

Results

Human milk oligosaccharides inhibit growth of group B *Streptococcus*

To evaluate the potential antimicrobial effect(s) of HMO on a group of bacterial pathogens, we resuspended ~10⁵ cfu of each bacterial overnight culture in serum-free tissue culture medium (RPMI) with or without 2 mg/ml of HMOs isolated from pooled human milk (pHMO) and then incubated for 4 h. pHMOs did not affect the growth of UPEC, *P. aeruginosa*, and methicillin-resistant *S. aureus*. However, growth of the GBS test strain (serotype III isolate COH1) was reduced by ~10-fold

(p < 0.05) (Fig. 1A). We confirmed that HMOs are bacteriostatic and not bactericidal because they did not kill GBS even at very high concentration (Fig. 1B). pHMO impaired the growth of the three most common GBS serotypes—serotypes III (strain COH1), Ia (strain A909), and V (strain NCTC10/84)—in a dose-dependent manner between 0.25–1.0 mg/ml (Fig. 1C).

The neutral fraction of HMOs possesses the GBS inhibitory activity

Galacto-oligosaccharides (GOS) are sometimes used to supplement infant formula to mimic the prebiotic properties of HMOs. However, GOS are structurally different from HMOs and consist of linear chains of two to six galactose residues linked to a single glucose. Unlike pHMOs, GOS did not impact GBS growth (Fig. 2A). Moreover, pHMOs pretreated with proteinase K retained their GBS-inhibitory activity (supplemental Fig. S1). Thus, pHMO-mediated inhibition of GBS growth is neither a nonspecific effect of oligosaccharides nor does it appear to require a protein.

Next, we separated pHMOs into sialylated, acidic HMOs (aHMOs) and non-sialylated, neutral HMOs (nHMOs) (9). Although nHMOs exerted a similar effect as pHMOs, aHMOs did not inhibit GBS growth (Fig. 2B). Consistent with this result, sialidase treatment of pHMOs to remove sialic acid moieties, which was confirmed by HPLC analysis, did not alter the inhibitory properties (Fig. 2C). At 1.0 mg/ml, nHMOs slowed serotype III GBS (COH1) growth by 98.2%, serotype Ia GBS (A909) growth by 97.0%, and serotype V GBS (NCTC10/84) growth by 96.0% (Fig. 2D). At a lower dose of 0.25 mg/ml, nHMOs inhibited growth of the serotype III and Ia GBS strains




Figure 2. The neutral fraction of human milk oligosaccharides exerts a bacteriostatic effect on GBS. A, GBS serotype III strain COH1 growth curve in the presence of 5 mg/ml of pooled HMOs or GOS in SF-RPMI medium. B, GBS growth in SF-RPMI supplemented with pHMO, nHMO, or aHMO. C, GBS growth in untreated pooled HMO (open circles) or sialidase-treated pooled HMO (closed circles). D, GBS strain COH1, A909, and NCTC growth in the presence of neutral HMO fractions at the indicated concentrations. Relative growth represents cfu at the indicated point with respect to initial cfu inoculum \times 100%. Error bars, S.E. ($n = 3$). ***, $p < 0.001$; **, $p < 0.01$; *, $p < 0.05$; ns, not significant; one-way ANOVA, Tukey's multiple comparison's test or Dunnett's post-test.

by more than 40-fold ($p < 0.01$), an effect more potent than pHMOs at the same dose (Fig. 1C).

Identification of neutral HMOs that inhibit GBS growth

To identify specific neutral oligosaccharide(s) responsible for GBS-inhibitory activity, we separated nHMOs into 10 fractions via size exclusion chromatography. We evaluated the bacteriostatic activity of each fraction by monitoring the GBS growth rate and found the strongest growth inhibition in the fourth and sixth size fractions (Fig. 3A). Based on HPLC profiles, these fractions primarily contained HMOs with up to eight monosaccharide moieties. Based on this lead, we selected nine commercially available oligosaccharides, each with slight modifications in the core structure known to exist in HMOs: lacto-*N*-tetraose (LNT), lacto-*N*-neotetraose (LNnT), lacto-*N*-neoheptaose (LNnH), lacto-*N*-fucopentaose I (LNFP1), lacto-*N*-difucohexaose II (LNDFHII), lacto-*N*-neooctaose (LnNO), lacto-*N*-neodifucohexaose (LNnDFH), lacto-*N*-neofucopentaose (LNnFPV), and lacto-*N*-fucopentaose V (LNFPV). GBS were challenged with 5 mg/ml of these individual oligosaccharides, and growth was observed to be significantly (60–70%) inhibited by LNT and its fucosylated derivative LNFP1 (Fig. 3B). Most intriguingly, the LNT structural isomer LNnT (Fig. 3C) showed no significant inhibition of GBS growth.

Disruption of GBS glycosyltransferase leads to resistance against HMOs

To identify bacterial factors involved in GBS susceptibility to HMOs, we screened \sim 1200 serotype III GBS (COH1) transposon Tn917 Δ E mutants from our previously published library (21) for resistance to growth suppression by 2.5 mg/ml of

pHMOs. This screen selected for a candidate mutant that exhibited normal growth over 7 h despite exposure to pHMOs (Fig. 4A). Through chromosomal sequence analysis, we identified the transposon insertion in this mutant to lie in the promoter of a gene annotated as *gbs0738*. Based on the Basic Local Alignment Search Tool (BLAST), *gbs0738* encodes a putative glycosyltransferase that belongs to the carbohydrate-active enzymes (CAZY) GT-8 family and is conserved among 18 group B *Streptococcus* subspecies, with high levels of identity (99%) in strains, including serotype Ia A909 and serotype V NCTC10/84 (supplemental Fig. S2). To confirm that the transposon Tn917 Δ E insertion was not accompanied by unlinked mutations in the genome, we created a targeted in-frame insertion mutant in the wild-type strain COH1 to create knockout strain Δ 0738. The targeted Δ 0738 mutant recapitulated the growth profile of the original transposon mutant and was not susceptible to the bacteriostatic effect of pHMO ($p > 0.05$) (Fig. 4, B and C). This finding confirms that the resistance to HMOs is specifically linked to inactivation of the *gbs0738* gene.

Of note, the GT-8 glycosyltransferase shares some sequence homology with LPS glycosyltransferase RfaJ, an important outer membrane biosynthesis protein in Gram-negative bacteria (22). Because GBS is a Gram-positive pathogen lacking an outer membrane, we postulated this glycosyltransferase could promiscuously catalyze the glycosylation of HMOs into polysaccharide components of the GBS capsule or incorporate them into peptidoglycan/glycan-binding proteins (*i.e.* lectins) in the GBS cell wall. To explore this hypothesis, we first monitored the growth kinetics of a GBS serotype III capsule-deficient mutant (strain HY106 (23)) in the presence of HMOs. We

Human milk oligosaccharides inhibit GBS growth




Figure 3. Identification of neutral HMO fraction(s) that block GBS growth. A and B, nHMOs were separated by size exclusion chromatography. A, a total of 10 fractions were isolated from 40 mg/ml neutral HMO. Relative growth of GBS within 2 h in each fraction (N1-N10 and RPMI as a control) is shown as $A_{600\text{ nm}} 4\text{ h}/2\text{ h}$, which represents the ratio of optical density measured at 4 h divided by the optical density measured at 2 h. B, relative GBS growth (cfu recovered with respect to initial inoculum) after 2 h of incubation in SF-RPMI alone (red columns) or supplemented with 5 mg/ml of individual commercially acquired neutral oligosaccharides (black columns). Relative growth represents cfu at indicated point with respect to initial cfu inoculum $\times 100\%$. *, $p < 0.01$; **, $p < 0.01$; ***, $p < 0.001$; one-way ANOVA, Tukey's post-test. C, structures of LNT, LNNt, and LNFPI. Blue circles, glucose; yellow circles, galactose; blue squares, N-acetyl-glucosamine; red triangle, fucose.




Figure 4. A GBS glycosyltransferase mutant is not susceptible to HMO-mediated killing. A, transposon library screening identified a mutant GBS that is resistant to HMO treatment. $100\ \mu\text{l}$ of GBS COH-1 ($A_{600} = 0.01$) is grown in SF-RPMI supplemented with 5 mg/ml of pHMO for 24 h at $37\ ^\circ\text{C}$. A_{600} was measured at 30-min intervals over 8 h through a Bioscreen C MBR system. Tn, transposon. B, growth curves of GBS COH1 WT (black) or $\Delta 0738$ targeted knockout (red) in serum-free RPMI media (solid lines) or with 5 mg/ml pHMO (dotted line) over 8 h at $37\ ^\circ\text{C}$. C, relative GBS growth after 4 h of incubation in SF-RPMI with or without 5 mg/ml of pHMO. D, growth curves of GBS COH1 WT (black), HY106 (red) and $\Delta iagA$ (blue) in SF-RPMI (solid lines) or with 5 mg/ml of neutral HMO (dotted lines). Relative growth represents cfu at the indicated point with respect to initial cfu inoculum $\times 100\%$. ***, $p < 0.001$; ns, not significant.

found that the capsule-deficient mutant still exhibited significant growth inhibition in the presence of nHMO (Fig. 4D), suggesting that the capsule is not targeted by nHMOs. To delineate whether GBS sensitivity to HMOs extends to the activity of other glycosyltransferases, we studied a GBS mutant ($\Delta iagA$) encoding a group 1 glycosyltransferase (21) that likewise remained sensitive to nHMO-mediated inhibition (Fig. 4D). Thus, our results suggest that GBS susceptibility to nHMOs

is attributed with some specificity to the *gbs0738*-encoded glycosyltransferase.

Synergistic activity of HMOs and antibiotics against GBS

In serious or difficult-to-treat infections, combination antibiotic therapy is often considered to exploit synergistic activities and to reduce the risk of generating antimicrobial resistance. We examined whether prior exposure to HMOs could




Figure 5. Neutral HMOs increase GBS sensitivity to antibiotics. A, IC_{50} curve of nHMOs. Cfu were recovered after 4 h of nHMO treatment at different concentrations. B and C, IC_{50} curves of vancomycin (B) and ciprofloxacin (C) in the presence (red) or absence (black) of 0.25 mg/ml of nHMOs that show GBS growth inhibition. Error bars, S.E. ($n = 3$). D, the interaction index calculation formula.

sensitize GBS to different pharmaceutical antibiotics. GBS growth was monitored over 4 h at different concentrations of nHMOs, and the IC_{50} was determined to be 0.899 mg/ml (Fig. 5A). We then measured the IC_{50} of GBS in the presence or absence of 0.25 mg/ml, a sub- IC_{50} of nHMOs, in the presence of the glycopeptide antibiotic vancomycin, the fluoroquinolone antibiotic ciprofloxacin, or the β -lactam antibiotic imipenem. The presence of nHMOs at a sub- IC_{50} concentration dramatically reduced the IC_{50} of both vancomycin (0.25 μ g/ml alone versus 0.00602 μ g/ml with nHMOs) and ciprofloxacin (1.37 μ g/ml alone versus 0.0021 μ g/ml with nHMOs) (Fig. 5, B and C) but did not improve the activity of imipenem (supplemental Fig. S3). Calculation of the interaction index (Fig. 5D) revealed the interaction between nHMO and vancomycin or ciprofloxacin to represent true synergism ($I < 0.5$).

Discussion

A growing body of evidence has documented a variety of protective properties of HMOs against infectious agents. In addition to modulating host immune responses (24, 25), oligosaccharides can pose as receptor decoys to prevent adhesion of microbial pathogens to epithelial surfaces (11–14). In a prior study, we demonstrated that HMOs, specifically the sialylated fraction of HMOs, and 3'-sialyllactose (3'SL) alone, support host innate defense and reduce invasion of UPEC into bladder epithelial cells. Conversely, in this study we found that certain neutral, non-sialylated forms of HMOs may cause a significant defect in GBS growth. To our knowledge, this is the first study to associate HMOs with a direct antimicrobial effect. Among the four bacterial species tested, the bacteriostatic effect of HMOs was unique to GBS.

Through a combination of mutation and bioinformatics analysis, we identified a conserved putative glycosyltransferase family 8 member (*gbs0738*) that is required for GBS sensitivity to HMOs. The predicted protein product of this GBS glycosyltransferase does not possess strong identity or similarity to genes from other bacterial species, which may explain why HMO inhibition is specific to GBS and not to other tested organisms (Fig. 1A). This particular family of glycosyltransferases is characterized by the GT-A fold and DXD motif. The GBS enzyme (*gbs0738*) shares high identity with an *E. coli* enzyme within this family of glycosyltransferases that is involved in synthesis of the outer core region of lipo-oligosaccharide, catalyzing the α -1,2 linkage of donor sugar to their acceptors (26). In *Streptococcus* spp., glycosyltransferases participate in the biosynthesis of capsular polysaccharides, cell wall peptidoglycan, and anchoring of lipoteichoic acid within the cell wall (27, 28). In GBS, glycosyltransferase-encoding *cpsE* is important for the synthesis of the surface polysaccharide capsules (29), and *iagA* is a glycosyltransferase that aids in the anchoring of lipoteichoic acid (21), but neither are essential for GBS growth (21, 29). GBS mutants lacking capsule or *IagA*, however, remain sensitive to HMOs. Our results suggest that growth inhibition by HMOs may depend on *gbs0738*-encoded glycosyltransferase to catalyze incorporation of HMO components into the cell wall. Ongoing work aims to biochemically characterize this glycosyltransferase and identify specific HMO substrates and GBS targets.

LNT causes the highest inhibition of GBS growth (Fig. 3B). LNT is one of the most abundant core structures in human milk (0.5–1.5 g/liter in mature human milk) (30). Further, LNT has

Human milk oligosaccharides inhibit GBS growth

been identified to block *Entamoeba histolytica* binding to epithelial cell surfaces (12). However, LNT has never been proposed to serve any direct antimicrobial function. One intriguing observation is that a slight conformational change of the single 3GlcNAc β 1 residue of LNT to 4GlcNAc β 1 in LNnT nearly abrogates its bacteriostatic effect on GBS (Fig. 3B). Our results suggest that there is a strict 3GlcNAc β 1 conformation requirement for maximal GBS inhibition.

HMOs have been found in the plasma (15, 16) and urine (17, 18) of breast-fed infants. Also, HMOs appear in the urine of pregnant women as early as the end of first trimester. Although the exact concentration of HMOs present in these areas is still uncertain, our results support the notion that lower incidences of GBS infections in breast-fed infants and already in pregnant women could include a contribution from the antibacterial properties of HMOs. Further, our demonstration of HMO synergism with certain pharmaceutical antibiotics suggests their potential utility in adjunctive therapy of GBS infection. Future animal studies as well as human cohort studies on human mother-infant dyads may help identify associations of individual HMOs like LNT with GBS infection risk. It is intriguing to envision the rational development of novel anti-infective strategies based on the natural template of human milk.

Experimental procedures

Bacterial strains, cells, media, and growth conditions

The wild-type GBS strain COH1 (serotype I and I) and its mutant derivatives HY106 and Δ *iagA* (21), A909 (serotype Ia), NCTC10/84 (serotype V), and methicillin-resistant *S. aureus* strain TCH1516 were grown overnight in Todd-Hewitt agar or Todd-Hewitt broth (THB). *P. aeruginosa* strain PA14 and UPEC strain CFT073 (O6:K2:H1, ATCC 700928) were grown overnight in Luria-Bertani agar or broth. All bacteria were propagated in standing culture to stationary phase at 37 °C in 5% CO₂ unless stated otherwise.

Human milk oligosaccharide isolations

pHMOs were prepared as described previously (31) and lyophilized for long-term storage. Milk from 36 different donors was pooled to account for heterogeneity in HMO composition between different women. The human milk donation program has been reviewed by the Institutional Review Board (IRB) Chair at University of California, San Diego and certified as exempt from IRB review under 45 CFR 46.101(b), category 4 because subjects cannot be identified and linked to generated data. Pooled HMOs were separated into aHMO and nHMO by anion exchange chromatography as described previously (31). nHMOs were further separated by size using size exclusion chromatography. pHMOs were dialyzed by incubation with neuraminidase from *Vibrio cholerae*. HMO composition was analyzed by high-performance liquid chromatography and mass spectrometry.

Sources of galacto-oligosaccharides and purified glycans

Galacto-oligosaccharides were generously provided by Friesland Campina Domo (the Netherlands). Purified glycans were purchased from ELICITYL OligoTech[®], which includes LNT,

LNnT, LNnH, LNFPI, LNDFHII, LnNO, LNnDFH, LNnFPV, and LNEPV.

GBS growth and susceptibility test

Overnight GBS growth was back-diluted to $A_{600} = 0.01$ in serum-free RPMI 1640 (SF-RPMI) (Life Technologies) or supplemented with pooled or fractions of HMOs. To measure growth, bacteria were grown in 100 μ l of medium at 37 °C. At 600 nm, absorbance was recorded at 30-min interval using the BioScreen instrument (Growth Curves USA). To detect growth in cfu, bacteria were grown in 100 μ l of medium at 37 °C in humidified air with 5% CO₂ over 2 or 4 h. Recombinant proteinase K (Roche) was used at 0.1 mg/ml.

GBS COH-1 transposon library

The transposon library was constructed as described previously (21). To screen for mutants resistant to HMOs, we normalized overnight cultures of transposon mutants to A_{600} of 0.1. Approximately 10 μ l of each mutant was cultured in 100 μ l of SF-RPMI supplemented with 5 mg/ml of pooled HMOs. Growth was monitored over an 8-h period at 37 °C by measuring optical density at 600 nm at a 30-min interval using a Bioscreen C MBR system.

GBS COH-1 Δ 0738 construct

To generate a targeted knockout, we cloned the *gbs0738* gene to the temperature-sensitive vector PHY304. Briefly, *gbs0738* was PCR-amplified with primers XhoI-*gbs0738*F (5'-CGATCTCGAGTGCTCAGGCACCTACAACCTG-3') + HindIII-*gbs0738*R (5'-CAGTAAGCTTAGCAGGCAAGTTCATCAAGAG-3') to generate a 300-bp amplicon. The purified PCR amplicon was digested with XhoI and HindIII and ligated into previously digested PHY304. The construct was cloned into *E. coli* DH5 α and isolated by mini-prep. Approximately 1 μ g of PHY304-*gbs0738* DNA was transformed into electrocompetent GBS at 1550 V. The transformed bacteria were allowed to recover in 500 μ l of THB with 0.25 M sucrose at 30 °C for 2 h while shaking at 220 RPM. Bacteria were grown overnight on Todd-Hewitt agar + 2 μ g/ml erythromycin at 30 °C. After 2–3 days, colonies were selected and inoculated into 5 ml of THB + 5 μ g/ml erythromycin at 30 °C overnight. The next day, cultures were prepared in duplicate in THB + erythromycin at 30 °C and 37 °C to select for bacteria with the targeting vector incorporated into the chromosome. Resultant single colonies from the 37 °C culture were isolated and confirmed for single crossover mutation by PCR using primers M13F (5'-GTTTTCCAGTCACGAC-3') and *gbs0738*R2 (5'-ACACGCTCCTCCTTTGATATT-3'). Wild-type GBS had an expected 1.67 kb PCR product, whereas the mutant had an expected 6.5-kbp PCR product.

Statistical analysis

All experiments were performed in triplicate or quadruplicate and repeated in at least two independent experiments. Error bars represent S.E. ($n > 3$) from multiple independent experiments. Statistical analysis was performed using Student's unpaired two-tailed *t* test or one-way ANOVA for multiple comparisons (GraphPad Prism version 5.03). *, $p < 0.05$; **, $p <$

0.01; and ***, $p < 0.001$ represent statistical significance. $p > 0.05$ represents non-significance. IC_{50} was calculated using non-linear regression curve fit using the equation $\log(\text{inhibitor})$ versus response-variable slope. Error bars represent S.E. ($n = 3$).

Author contributions—A. E. L. designed and performed the experiments, analyzed the data, prepared the figures, and co-wrote the manuscript. C. A. A., A. S., M. H., K. G., and T. E. performed the experiments. A. R. P. and G. J. B. provided the desialylated HMOs. K. S. D. provided the GBS transposon library. A. L. L. and K. G. participated in data analysis. L. B. and V. N. designed the experiments, participated in data analysis, and co-wrote the manuscript.

Acknowledgments—We thank Samira Dahesh for expertise regarding GBS cloning and Federico C. Beasley for helpful discussions regarding data interpretation and critical review of the manuscript.

References

- Edwards, M. S. (2006) Issues of antimicrobial resistance in group B streptococcus in the era of intrapartum antibiotic prophylaxis. *Semin. Pediatr. Infect. Dis.* **17**, 149–152
- Heath, P. T., and Schuchat, A. (2007) Perinatal group B streptococcal disease. *Best. Pract. Res. Clin. Obstet. Gynaecol.* **21**, 411–424
- Thigpen, M. C., Whitney, C. G., Messonnier, N. E., Zell, E. R., Lynfield, R., Hadler, J. L., Harrison, L. H., Farley, M. M., Reingold, A., Bennett, N. M., Craig, A. S., Schaffner, W., Thomas, A., Lewis, M. M., Scallan, E., et al. (2011) Bacterial meningitis in the United States, 1998–2007. *N. Engl. J. Med.* **364**, 2016–2025
- Phares, C. R., Lynfield, R., Farley, M. M., Mohle-Boetani, J., Harrison, L. H., Petit, S., Craig, A. S., Schaffner, W., Zansky, S. M., Gershman, K., Stefonek, K. R., Albanese, B. A., Zell, E. R., Schuchat, A., Schrag, S. J., and Active Bacterial Core Surveillance/Emerging Infections Program Network (2008) Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005. *JAMA* **299**, 2056–2065
- Bedford, H., de Louvois, J., Halket, S., Peckham, C., Hurley, R., and Harvey, D. (2001) Meningitis in infancy in England and Wales: follow up at age 5 years. *BMJ* **323**, 533–536
- Edmond, K. M., Kortsalioudaki, C., Scott, S., Schrag, S. J., Zaidi, A. K., Cousens, S., and Heath, P. T. (2012) Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. *Lancet* **379**, 547–556
- Baltimore, R. S. (2007) Consequences of prophylaxis for group B streptococcal infections of the neonate. *Semin. Perinatol.* **31**, 33–38
- Castor, M. L., Whitney, C. G., Como-Sabetti, K., Facklam, R. R., Ferrieri, P., Bartkus, J. M., Juni, B. A., Cieslak, P. R., Farley, M. M., Dumas, N. B., Schrag, S. J., and Lynfield, R. (2008) Antibiotic resistance patterns in invasive group B streptococcal isolates. *Infect. Dis. Obstet. Gynecol.* **2008**, 727505
- Bode, L., and Jantscher-Krenn, E. (2012) Structure-function relationships of human milk oligosaccharides. *Adv. Nutr.* **3**, 383S–391S
- Bode, L. (2012) Human milk oligosaccharides: every baby needs a sugar mama. *Glycobiology* **22**, 1147–1162
- Martín-Sosa, S., Martín, M. J., and Hueso, P. (2002) The sialylated fraction of milk oligosaccharides is partially responsible for binding to enterotoxigenic and uropathogenic *Escherichia coli* human strains. *J. Nutr.* **132**, 3067–3072
- Jantscher-Krenn, E., Lauwaet, T., Bliss, L. A., Reed, S. L., Gillin, F. D., and Bode, L. (2012) Human milk oligosaccharides reduce *Entamoeba histolytica* attachment and cytotoxicity *in vitro*. *Br. J. Nutr.* **108**, 1839–1846
- Newburg, D. S., Pickering, L. K., McCluer, R. H., and Cleary, T. G. (1990) Fucosylated oligosaccharides of human milk protect suckling mice from heat-stable enterotoxin of *Escherichia coli*. *J. Infect. Dis.* **162**, 1075–1080
- Newburg, D. S. (2005) Innate immunity and human milk. *J. Nutr.* **135**, 1308–1312
- Ruhaak, L. R., Stroble, C., Underwood, M. A., and Lebrilla, C. B. (2014) Detection of milk oligosaccharides in plasma of infants. *Anal. Bioanal. Chem.* **406**, 5775–5784
- Goehring, K. C., Kennedy, A. D., Prieto, P. A., and Buck, R. H. (2014) Direct evidence for the presence of human milk oligosaccharides in the circulation of breastfed infants. *PLoS ONE* **9**, e101692
- Rudloff, S., Obermeier, S., Borsch, C., Pohlentz, G., Hartmann, R., Brösicke, H., Lentze, M. J., and Kunz, C. (2006) Incorporation of orally applied ^{13}C -galactose into milk lactose and oligosaccharides. *Glycobiology* **16**, 477–487
- Dotz, V., Rudloff, S., Meyer, C., Lochnit, G., and Kunz, C. (2015) Metabolic fate of neutral human milk oligosaccharides in exclusively breast-fed infants. *Mol. Nutr. Food Res.* **59**, 355–364
- Hallgren, P., and Lundblad, A. (1977) Structural analysis of nine oligosaccharides isolated from the urine of a blood group O, nonsecretor, woman during pregnancy and lactation. *J. Biol. Chem.* **252**, 1014–1022
- Lin, A. E., Autran, C. A., Espanola, S. D., Bode, L., and Nizet, V. (2014) Human milk oligosaccharides protect bladder epithelial cells against uropathogenic *Escherichia coli* invasion and cytotoxicity. *J. Infect. Dis.* **209**, 389–398
- Doran, K. S., Engelson, E. J., Khosravi, A., Maisey, H. C., Fedtke, I., Equils, O., Michelsen, K. S., Arditi, M., Peschel, A., and Nizet, V. (2005) Blood-brain barrier invasion by group B *Streptococcus* depends upon proper cell-surface anchoring of lipoteichoic acid. *J. Clin. Invest.* **115**, 2499–2507
- Parker, C. T., Pradel, E., and Schnaitman, C. A. (1992) Identification and sequences of the lipopolysaccharide core biosynthetic genes rfaQ, rfaP, and rfaG of *Escherichia coli* K-12. *J. Bacteriol.* **174**, 930–934
- Yim, H. H., Nittayarin, A., and Rubens, C. E. (1997) Analysis of the capsule synthesis locus, a virulence factor in group B streptococci. *Adv. Exp. Med. Biol.* **418**, 995–997
- He, Y., Liu, S., Kling, D. E., Leone, S., Lawlor, N. T., Huang, Y., Feinberg, S. B., Hill, D. R., and Newburg, D. S. (2016) The human milk oligosaccharide 2'-fucosyllactose modulates CD14 expression in human enterocytes, thereby attenuating LPS-induced inflammation. *Gut* **65**, 33–46
- Li, M., Monaco, M. H., Wang, M., Comstock, S. S., Kuhlenschmidt, T. B., Fahey, G. C., Jr., Miller, M. J., Kuhlenschmidt, M. S., and Donovan, S. M. (2014) Human milk oligosaccharides shorten rotavirus-induced diarrhea and modulate piglet mucosal immunity and colonic microbiota. *ISMEJ*, **8**, 1609–1620
- Leipold, M. D., Vinogradov, E., and Whitfield, C. (2007) Glycosyltransferases involved in biosynthesis of the outer core region of *Escherichia coli* lipopolysaccharides exhibit broader substrate specificities than is predicted from lipopolysaccharide structures. *J. Biol. Chem.* **282**, 26786–26792
- Miyake, K., and Iijima, S. (2004) Bacterial capsular polysaccharide and sugar transferases. *Adv. Biochem. Eng. Biotechnol.* **90**, 89–111
- Shainheit, M. G., Valentino, M. D., Gilmore, M. S., and Camilli, A. (2015) Mutations in pneumococcal cpsE generated via *in vitro* serial passaging reveal a potential mechanism of reduced encapsulation utilized by a conjunctival isolate. *J. Bacteriol.* **197**, 1781–1791
- Cieslewicz, M. J., Kasper, D. L., Wang, Y., and Wessels, M. R. (2001) Functional analysis in type Ia group B *Streptococcus* of a cluster of genes involved in extracellular polysaccharide production by diverse species of streptococci. *J. Biol. Chem.* **276**, 139–146
- Pfenninger, A., Karas, M., Finke, B., and Stahl, B. (2002) Structural analysis of underivatized neutral human milk oligosaccharides in the negative ion mode by nano-electrospray MS(n) (part 2: application to isomeric mixtures). *J. Am. Soc. Mass Spectrom.* **13**, 1341–1348
- Jantscher-Krenn, E., Zhrebtsov, M., Nissan, C., Goth, K., Guner, Y. S., Naidu, N., Choudhury, B., Grishin, A. V., Ford, H. R., and Bode, L. (2012) The human milk oligosaccharide disialyllacto-N-tetraose prevents necrotizing enterocolitis in neonatal rats. *Gut* **61**, 1417–1425

SUPPLEMENTAL MATERIAL

Human Milk Oligosaccharides Inhibit Growth of Group B *Streptococcus*

Ann E. Lin¹, Chloe A. Aufran^{2,3}, Alexandra Szyszka^{2,3}, Tamara Escajadillo¹, Mia Huang⁴,
Kamil Godula⁴, Anthony R. Prudden⁷, Geert-Jan Boons⁷, Amanda L. Lewis⁸,
Kelly S. Doran^{1,9}, Victor Nizet^{1,5,6} and Lars Bode^{2,3,6,10*}

Figure S1	GBS growth in pHMO with or without proteinase K	Page S2
Figure S2	<i>gbs0738</i> AA sequence alignment.	Page S3
Figure S3	Imipenem and HMO co-treatment.....	Page S4




Figure S1. GBS growth in pHMO with or without proteinase K. GBS serotype III strain COH1 was incubated in SF-RPMI alone (red), with 5 mg/mL pHMO (black), or with addition of 0.1 mg/mL of Proteinase K (gray) over 6 h.

Description	Max Score	Total Score	Query Cover	E Value	Identity	Accession
glycosyl transferase [Streptococcus agalactiae]	425	492	70%	3e-147	83%	WP_001050372.1
glycosyl transferase [Streptococcus agalactiae]	424	493	70%	1e-146	83%	WP_001050371.1
glycosyl transferase [Streptococcus agalactiae]	423	489	70%	3e-146	82%	WP_060458432.1
glycosyl transferase [Streptococcus agalactiae]	423	493	70%	3e-146	82%	WP_001050374.1
glycosyl transferase [Streptococcus agalactiae]	423	493	70%	3e-146	82%	WP_047205463.1
glycosyl transferase [Streptococcus agalactiae]	422	492	70%	4e-146	82%	WP_050196718.1
glycosyl transferase [Streptococcus agalactiae]	422	490	70%	5e-146	82%	WP_049426322.1
glycosyl transferase [Streptococcus agalactiae]	421	490	70%	1e-145	82%	WP_001050373.1
UDP-galactose--LPS alpha 1,2-galactosyltransferase WaaW [Streptococcus agalactiae]	421	491	70%	2e-145	82%	WP_016480665.1
glycosyl transferase [Streptococcus agalactiae]	421	490	70%	2e-145	82%	WP_001050375.1
glycosyl transferase [Streptococcus agalactiae]	417	486	70%	9e-144	81%	WP_001050370.1
glycosyl transferase [Streptococcus agalactiae]	379	379	50%	4e-130	99%	WP_017648715.1

glycosyl transferase [Streptococcus agalactiae]
Sequence ID: [ref|WP_001050372.1|](#) Length: 272 Number of Matches: 2
Identical Proteins-Identical proteins to WP_001050372.1

Score	Expect	Method	Identities	Positives	Gaps	Frame
425 bits(1093) 3e-147 Compositional matrix adjust. 222/269(83%) 229/269(85%) 16/269(5%) +1						
Query	70	LDDMYVDHFKVMLYSLVRQTKNRKLEIYVLQKTLTKRHELIQYTQNLEVGYPHPIIVGTE				249
Sbjct	7	+DDMYVDHFKVMLYSLVRQTKNRKLEIYVLQKTLTKRHELIQYTQNLEVGYPHPIIVGTE				66
Query	250	VFAQAPTDRYPDTIYYRLLAHKFLPETLDRILYLDADMLCLNDFSSLYDMELGDQLYAA				429
Sbjct	67	VFAQAPTDRYPDTIYYRLLAHKFLPETLDRILYLDADMLCLNDFSSLYDMELGDQLYAA				126
Query	430	ASHNTDGKFLDYVNKLRLKNVELESSYFNTGVLLMNLPAIRKVVHQQTILDYIMQNRGRL				609
Sbjct	127	ASHNTDGKFLDYVNKLRLKNVELESSYFNTGVLLMNLPAIRKVVHQQTILDYIMQNRGRL				186
Query	610	ILPDQDILNGLYANLVNQYPMKF-----IIMMLGIVLFIN*KVAMNGI*SGY*PYCF				765
Sbjct	187	ILPDQDILNGLYANLV P + + + I L + + + N F				239
Query	766	LHFAGRDNMEKKIYRGRYSGLYS-AKEA	849			
Sbjct	240	LHFAGRD KK YRGRYSGLY + AKEA	268			

Figure S2. *gbs0738* AA sequence alignment




Figure S3. Imipenem and HMO co-treatment. HMO did not exhibit synergy with the antibiotic imipenem. IC_{50} curves of imipenem are depicted in the presence (red) or absence (black) of 0.25 mg/mL of nHMO that show GBS growth inhibition. Error bar= S.E, (n = 3).